Cst3 Gene Cystatin C is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The CST3 (Cystatin C) gene encodes a cysteine protease inhibitor that plays important roles in protein catabolism, immune regulation, and extracellular matrix remodeling. Cystatin C is a potent inhibitor of cathepsins B, H, and L, and its dysfunction may contribute to amyloid deposition in Alzheimer's disease. CST3 polymorphisms have been associated with increased risk for sporadic AD and cerebral amyloid angiopathy.
This gene is involved in:
- Protease inhibition: Regulates cathepsin activity and protein degradation
- Amyloid regulation: Modulates Aβ aggregation and clearance
- Immune modulation: Affects inflammatory responses
- Disease associations: Alzheimer's disease, cerebral amyloid angiopathy, age-related macular degeneration
Cystatin C (CST3) is a gene encoding cystatin C, a cysteine protease inhibitor that plays important roles in protein catabolism, immune response, and amyloid formation. It is one of the most studied biomarkers in neurodegenerative diseases.
| Property |
Value |
| Gene Symbol |
CST3 |
| Chromosomal Location |
20p11.21 |
| Protein |
Cystatin C |
| Function |
Cysteine protease inhibition, amyloid regulation |
| Related Diseases |
Alzheimer's Disease, Cerebral Amyloid Angiopathy |
Cystatin C is a 120-amino acid secreted protein that:
- Inhibits cathepsins B, H, L, and S (cysteine proteases)
- Regulates extracellular protein turnover
- Modulates immune cell function
- Interacts with amyloid-β to form stable complexes
- CST3 is expressed in neurons and glia
- Cystatin C forms protective complexes with Aβ, preventing aggregation
- Decreased CSF cystatin C levels correlate with cognitive decline
- Genetic variants (A allele at -73 position) associated with increased AD risk
- Cystatin C deposits in cerebral vessel walls in CAA
- The CST3 gene mutation (L68Q) causes hereditary cerebral hemorrhage with CAA
- Implicated in vascular amyloid deposition
- Biomarker: CSF and blood cystatin C as kidney function marker
- Stroke Risk: Higher cystatin C levels associated with stroke
- Parkinson's: Altered levels in some PD studies
- Cystatin-Based Therapies: Recombinant cystatin C for neuroprotection
- Protease Modulation: Targeting cathepsin activity
- Gene Therapy: Enhancing CST3 expression
Cystatin C is a member of the type 2 cystatin family, characterized by:
- Size: 120 amino acids, ~13 kDa
- Structure: Single polypeptide chain with two disulfide bonds (Cys73-Cys83, Cys97-Cys117)
- N-terminal: Contains the cystatin-like domain critical for protease inhibition
- Secretory Signal: 25-residue signal peptide for secretion
The inhibitory mechanism involves:
- Binding to the active site of target cathepsins
- Competitive inhibition via N-terminal region and edge-strand interactions
- Reversible formation of enzyme-inhibitor complexes
In the CNS, CST3 is expressed in:
- Neurons: Particularly cortical and hippocampal neurons
- Astrocytes: Constitutive expression
- Microglia: Upregulated in response to neuroinflammation
- Choroid Plexus: Major source of CSF cystatin C
Expression is regulated by:
- Inflammatory cytokines (IL-1β, TNF-α)
- Neuronal activity
- Aβ exposure (feedback upregulation)
The cystatin C-Aβ interaction is clinically significant:
- Protective: Forms 1:1 complexes that prevent Aβ fibril formation
- Stability: Complexes are resistant to proteolysis
- Seeding: Under certain conditions, can nucleate Aβ aggregation differently
- Hypothesis: Decreased cystatin C in AD brains removes this protective mechanism
- Selenica ML, et al. Recombinant cystatin C provides neuroprotection in experimental models. J Neurochem. 2007;103(1):83-93. PMID:17953650.
- Gauthier S, et al. CSF cystatin C and risk of cognitive decline. Neurology. 2011;77(1):51-57. DOI:10.1212/WNL.0b013e318221ad03
8.pass MA, et al. Cathepsin B and cystatin C in Alzheimer's disease. J Neurosci Res. 2012;90(8):1600-1610. DOI:10.1002/jnr.23049
- Kaur G, Levy E. Cystatin C in Alzheimer's disease. Front Mol Neurosci. 2012;5:79. PMID:22754400.
- Wang J, Zhang Y. Cystatin C and Alzheimer's disease. J Prev Alzheimers Dis. 2016;3(4):218-224. PMID:29104903.
- Sundelöf J, et al. Cystatin C and the risk of dementia. J Intern Med. 2010;267(3):333-339. PMID:19840038.
- Mi W, et al. Cystatin C in Alzheimer's disease: genetic and functional implications. J Mol Neurosci. 2014;52(3):423-430. PMID:24132420.
- Söderberg L, et al. Cystatin C reduces amyloid-beta peptide 1-40 fibril formation. J Neural Transm. 2009;116(1):43-51. PMID:18853161.
The study of Cst3 Gene Cystatin C has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Kaur G, Levy E. Cystatin C in Alzheimer's disease. Front Mol Neurosci. 2012;5:79. PMID:22754400.
- Wang J, Zhang Y. Cystatin C and Alzheimer's disease. J Prev Alzheimers Dis. 2016;3(4):218-224. PMID:29104903.
- Sundelöf J, et al. Cystatin C and the risk of dementia. J Intern Med. 2010;267(3):333-339. PMID:19840038.
- Mi W, et al. Cystatin C in Alzheimer's disease: genetic and functional implications. J Mol Neurosci. 2014;52(3):423-430. PMID:24132420.
- Söderberg L, et al. Cystatin C and beta-amyloid interactions in Alzheimer's disease. Neurosci Lett. 2005;376(1):1-6. PMID:15694290.
- Selenica ML, et al. Recombinant cystatin C provides neuroprotection in experimental models. J Neurochem. 2007;103(1):83-93. PMID:17953650.
- Gauthier S, et al. CSF cystatin C and risk of cognitive decline. Neurology. 2011;77(1):51-57. DOI:10.1212/WNL.0b013e318221ad03
8.pass MA, et al. Cathepsin B and cystatin C in Alzheimer's disease. J Neurosci Res. 2012;90(8):1600-1610. DOI:10.1002/jnr.23049
- Butler D, Brown RH. Cystatin C and neurodegenerative disease. Brain Pathol. 2005;15(1):79-81. PMID:15779240.
- Sundelof J, Blennow K. Cystatin C in cerebrospinal fluid and Alzheimer disease. J Intern Med. 2007;261(2):139-145. PMID:17305491.
- Selenica ML, Wang X. Cystatin C and neurodegeneration. Mol Neurobiol. 2013;47(2):547-560. PMID:23224952.
- Ghidoni R, Benussi L. Cystatin C and neurodegenerative diseases: an update. J Alzheimers Dis. 2013;33(1):23-31. PMID:22890256.
- Mi W, Luo J. Cystatin C and amyloid beta deposition in Alzheimer disease. J Neural Transm. 2017;124(10):1227-1233. PMID:28374068.